Whitepaper

elive™ characterizes immunotherapy response in live tumor fragments from patient biopsies

We describe our ex vivo platform for assessing immune checkpoint inhibitor response using live tumor tissue while preserving large areas of the contiguous native tumor microenvironment.  Using a sequential treatment strategy, we mitigate tumor heterogeneity challenges exacerbated when tissue amount is scarce.

Whitepaper

elive™ Edge: An automated cutting instrument used to produce live tumor fragments for the assessment of immunotherapy response ex vivo

This white paper introduces elive™ Edge, an automated cutting instrument used to precisely cut clinically relevant tissue form factors, such as core needle biopsies (CNBs), while preserving large contiguous areas of the native tumor microenvironment (TME).

Whitepaper

A novel sequential treatment strategy to address tissue scarcity and mitigate heterogeneity in live tumor fragments generated from core needle biopsies

This white paper demonstrates that elive™ Method is an effective approach for measuring cytokine response to immune checkpoint inhibition (ICI) from live tumor fragments (LTFs) in a setting where tissue amount is limited, such as in core needle biopsies (CNBs).

Whitepaper

Encapsulation of live tumor fragments in elive™ Gel preserves the native tumor microenvironment during ex vivo culture

This white paper presents data demonstrating that elive™ Gel, a proprietary hydrogel, preserves features of the native tumor microenvironment (TME)
in live tumor fragments (LTFs) during ex vivo culture.

Video

Overview of elive™ Method poster presented at ASCO 2025